Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients

International Journal of Cancer

Volumn 132, Issue 11, 2013, Pages 2520-2527

  Azad, Abul Kalam ^a   Bairati, Isabelle ^b   Qiu, Xin ^a   Huang, Huayi ^c   Cheng, Dangxiao ^a   Liu, Geoffrey ^a,d,e   Meyer, Francois ^b   Adjei, Araba ^c   Xu, Wei ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

genetic sequence variant; head and neck cancer; overall survival; second primary cancer; serum vitamin D level

Indexed keywords

VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYP24A1 GENE; CYP27A1 GENE; CYP27B1 GENE; CYP2R1 GENE; FEMALE; FOLLOW UP; GC GENE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VDR GENE; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM;

ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 ENZYME SYSTEM; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, CALCITRIOL; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VITAMIN D;

EID: 84875635199     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27946     Document Type: Article

References (40)

1. Robsahm TE, Tretli S, Dahlback A, et al. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004; 15: 149-58.
2. Zhou W, Heist RS, Liu G, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 2007; 25: 479-85.
3. Lipworth L, Rossi M, McLaughlin JK, et al. Dietary vitamin D and cancers of the oral cavity and esophagus. Ann Oncol 2009; 20: 1576-81.
4. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684-96.
5. Tangrea J, Helzlsouer K, Pietinen P, et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 1997; 8: 615-25.
6. Rossi M, McLaughlin JK, Lagiou P, et al. Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol 2009; 20: 374-8.
7. Lefkowitz ES, Garland CF,. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994; 23: 1133-6.
8. Hanchette CL, Schwartz GG,. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861-9.
9. Orell-Kotikangas H, Schwab U, Osterlund P, et al. High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis. Head Neck 2012; 34: 1450-5.
10. Arem H, Weinstein SJ, Horst RL, et al. Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men. Cancer Epidemiol Biomarkers Prev 2011; 20: 1178-84.
11. Meyer F, Liu G, Douville P, et al. Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. Int J Cancer 2011; 128: 1741-6.
12. Orton SM, Morris AP, Herrera BM, et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 2008; 88: 441-7.
13. Hunter D, De Lange M, Snieder H, et al. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 2001; 16: 371-8.
14. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010; 19: 2739-45.
15. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376: 180-8.
16. McCullough ML, Bostick RM, Mayo TL,. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 2009; 29: 111-32.
17. Deeb KK, Trump DL, Johnson CS,. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700.
18. Hama T, Norizoe C, Suga H, et al. Prognostic significance of vitamin D receptor polymorphisms in head and neck squamous cell carcinoma. PLoS One 2011; 6: e29634.
19. Anderson LN, Cotterchio M, Cole DE, et al. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 2011; 20: 1708-17.
20. Barroso E, Fernandez LP, Milne RL, et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer 2008; 8: 385.
21. Karami S, Brennan P, Rosenberg PS, et al. Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk. PLoS One 2009; 4: e7013.
22. Holt SK, Kwon EM, Koopmeiners JS, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010; 70: 1448-60.
23. Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003; 95: 1765-71.
24. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005; 97: 481-8.
25. Warren S, Gates O,. Multiple primary malignant tumor: a survey of the literature and a statistical study. Am J Cancer 1932; 16: 1358-414.
26. Lefor AT, Bredenberg CE, Kellman RM, et al. Multiple malignancies of the lung and head and neck. Second primary tumor or metastasis? Arch Surg 1986; 121: 265-70.
27. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
28. Azad AK, Bairati I, Samson E, et al. Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. Cancer 2012; 118: 1554-65.
29. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
30. Flohil SC, de Vries E, van Meurs JB, et al. Vitamin D-binding protein polymorphisms are not associated with development of (multiple) basal cell carcinomas. Exp Dermatol 2011; 19: 1103-5.
31. McCullough ML, Stevens VL, Diver WR, et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 2007; 9: R9.
32. Sinotte M, Diorio C, Berube S, et al. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 2009; 89: 634-40.
33. Lauridsen AL, Vestergaard P, Nexo E,. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the GC phenotype in women. Clin Chem 2001; 47: 753-6.
34. Strushkevich N, Usanov SA, Plotnikov AN, et al. Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol 2008; 380: 95-106.
35. Cheng JB, Levine MA, Bell NH, et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 2004; 101: 7711-5.
36. Roff A, Wilson RT,. A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J Steroid Biochem Mol Biol 2008; 112: 47-54.
37. Chen G, Kim SH, King AN, et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res 2011; 17: 817-26.
38. King AN, Beer DG, Christensen PJ, et al. The vitamin D/CYP24A1 story in cancer. Anticancer Agents Med Chem 2010; 10: 213-24.
39. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25: 144-6.
40. Ahn J, Albanes D, Berndt SI, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009; 30: 769-76.